BRPI0909493A2 - composições, métodos e kits - Google Patents

composições, métodos e kits

Info

Publication number
BRPI0909493A2
BRPI0909493A2 BRPI0909493A BRPI0909493A BRPI0909493A2 BR PI0909493 A2 BRPI0909493 A2 BR PI0909493A2 BR PI0909493 A BRPI0909493 A BR PI0909493A BR PI0909493 A BRPI0909493 A BR PI0909493A BR PI0909493 A2 BRPI0909493 A2 BR PI0909493A2
Authority
BR
Brazil
Prior art keywords
kits
compositions
methods
Prior art date
Application number
BRPI0909493A
Other languages
English (en)
Inventor
Keil Dan
Campos Manuel
Harland Richard
Plocher Thomas
Johnson Todd
Harbison Trent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40757034&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909493(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0909493A2 publication Critical patent/BRPI0909493A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/285—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
BRPI0909493A 2008-03-28 2009-03-20 composições, métodos e kits BRPI0909493A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4026008P 2008-03-28 2008-03-28
PCT/EP2009/053281 WO2009118273A1 (en) 2008-03-28 2009-03-20 Compositions, methods and kits

Publications (1)

Publication Number Publication Date
BRPI0909493A2 true BRPI0909493A2 (pt) 2017-11-07

Family

ID=40757034

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909493A BRPI0909493A2 (pt) 2008-03-28 2009-03-20 composições, métodos e kits

Country Status (15)

Country Link
US (2) US9046528B2 (pt)
EP (1) EP2262828B1 (pt)
KR (1) KR101647159B1 (pt)
CN (1) CN101981052B (pt)
AR (1) AR071104A1 (pt)
BR (1) BRPI0909493A2 (pt)
CA (1) CA2719041C (pt)
CL (1) CL2009000768A1 (pt)
CO (1) CO6290771A2 (pt)
ES (1) ES2551699T3 (pt)
HK (1) HK1149770A1 (pt)
MX (1) MX2010010614A (pt)
PL (1) PL2262828T3 (pt)
RU (1) RU2555530C2 (pt)
WO (1) WO2009118273A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2262828T3 (pl) 2008-03-28 2016-03-31 Elanco Tiergesundheit Ag Kompozycje, sposoby i zestawy
EP2561063B1 (en) * 2010-04-23 2017-01-04 Intervet International B.V. A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5
CN102399724B (zh) * 2011-11-08 2013-01-02 山东省农业科学院畜牧兽医研究所 一种副猪嗜血杆菌lc株及其应用
CN104404056B (zh) * 2014-11-12 2017-07-18 四川农业大学 一种重组副猪嗜血杆菌免疫保护性抗原HbpA2及其制备方法
CN104306964B (zh) * 2014-11-12 2017-10-10 四川农业大学 重组副猪嗜血杆菌免疫保护性抗原HbpA2的用途及用其制备的亚单位疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713071B1 (en) * 1998-10-22 2004-03-30 Pfizer Inc. Proteins from actinobacillus pleuropneumoniae
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
RU2268933C1 (ru) * 2004-04-21 2006-01-27 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) ШТАММ Haemophilus parasuis СК-1 - ВОЗБУДИТЕЛЬ ГЕМОФИЛЕЗНОГО ПОЛИСЕРОЗИТА СВИНЕЙ ДЛЯ ИЗГОТОВЛЕНИЯ ДИАГНОСТИЧЕСКИХ И ВАКЦИННЫХ ПРЕПАРАТОВ
WO2006132893A2 (en) * 2005-06-07 2006-12-14 Buck Institute For Age Research Sialic acid abc transporters in prokaryotes therapeutic targets
PL2262828T3 (pl) 2008-03-28 2016-03-31 Elanco Tiergesundheit Ag Kompozycje, sposoby i zestawy
WO2011056954A2 (en) * 2009-11-04 2011-05-12 Regents Of The University Of Minnesota Haemophilus parasuis polypeptides and methods of use

Also Published As

Publication number Publication date
CA2719041C (en) 2016-08-16
EP2262828B1 (en) 2015-09-30
HK1149770A1 (en) 2011-10-14
KR101647159B1 (ko) 2016-08-09
EP2262828A1 (en) 2010-12-22
CN101981052B (zh) 2014-11-26
CL2009000768A1 (es) 2011-07-01
CN101981052A (zh) 2011-02-23
CA2719041A1 (en) 2009-10-01
RU2555530C2 (ru) 2015-07-10
KR20100139096A (ko) 2010-12-31
CO6290771A2 (es) 2011-06-20
WO2009118273A1 (en) 2009-10-01
US20110014225A1 (en) 2011-01-20
ES2551699T3 (es) 2015-11-23
US10261092B2 (en) 2019-04-16
US9046528B2 (en) 2015-06-02
AR071104A1 (es) 2010-05-26
US20150293118A1 (en) 2015-10-15
RU2010143903A (ru) 2012-05-10
MX2010010614A (es) 2010-11-09
PL2262828T3 (pl) 2016-03-31

Similar Documents

Publication Publication Date Title
BRPI0919575A2 (pt) método, e, composição
BRPI0906474A2 (pt) Certas entidades químicas, composições e métodos
BRPI0912046A2 (pt) composições de hibridização e métodos
BRPI0920284A2 (pt) composição e método
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0809573A2 (pt) composição, e, método
BRPI0823277A2 (pt) Composição, e , método
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
DK3056214T3 (da) Hidtil ukendte adjuvanssammensætninger
DK2634232T3 (da) Sammensætninger
BRPI0909770A2 (pt) Vacina, e, kit
BRPI0913227A2 (pt) método, e objeto
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0917231A2 (pt) composição
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0814167A2 (pt) Composição, e, método
BRPI0823238A2 (pt) Composição, e, método
BRPI0917172A2 (pt) Composição bacteriana
BRPI0911625A2 (pt) Métodos
BRPI1006996A2 (pt) composição, método e uso
BRPI0822472A2 (pt) Método, camundongo, e, composição
BRPI0814748A2 (pt) Compostos de alditóis substituídos, composições e métodos
BRPI0809678A2 (pt) Métodos

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: NOVARTIS AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS TIERGESUNDHEIT AG (CH)

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: NOVARTIS TIERGESUNDHEIT AG (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ELANCO TIERGESUNDHEIT AG (CH)

B25G Requested change of headquarter approved

Owner name: ELANCO TIERGESUNDHEIT AG (CH)

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2455 DE 23/01/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal